ArticleFrontiers in immunology2024
CoviWall, a whole-virion-inactivated B.1.617.2 vaccine candidate, induces potent humoral and Th1 cell response in mice and protects against B.1.617.2 strain challenge in Syrian hamsters.
Article in Frontiers in immunology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
26 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Rapid development of coronavirus disease 2019 (COVID-19) vaccines and antiviral drugs have significantly reduced morbidity and mortality worldwide. Although most of the vaccines were developed initially with the ancestral Wuhan antigen, here, we report the development and immunological efficacy of a whole-virion-inactivated vaccine candidate (CoviWall) to combat the deadly B.1.617.2 (Delta strain) infection. In the current study, we demonstrate a consistent manufacturing process under Good Manufacturing Practice for the development of CoviWall and its characterization using various analytical methods as per regulatory compliance. In addition, we provide pre-clinical immunogenicity and protective efficacy data of the CoviWall vaccine. All the three test doses (i.e., low dose, mid dose, and high dose) immunized in C57BL/6 mice elicited a high titer of anti-receptor-binding domain antibody and neutralizing antibody response against severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) after second booster dose. In addition, CoviWall immunization also produced a significant T-cell response in the immunized animals. Our B.1.617.2 strain challenge data in Syrian hamsters indicate that immunized hamsters show attenuated clinical manifestations of COVID-19 with reduced lung viral load. Moreover, assessment of pulmonary histopathology revealed lower cellular injury, inflammation, and pneumonia in the vaccinated hamsters as compared to the unvaccinated animals. Such promising results augur well for the clinical phase I trial of the CoviWall vaccine and further development against contagious SARS-CoV-2 strains in the future.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.